Moleculin Biotech Croissance future

Future contrôle des critères 0/6

Les bénéfices de Moleculin Biotech devraient diminuer de 2.3% par an. Le BPA devrait augmenter de 27.4% par an.

Informations clés

-2.3%

Taux de croissance des bénéfices

27.4%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.3%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	18 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

Dec 20

Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?

Jul 14

Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?

Feb 18

Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Nov 01

Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies

Sep 27

Moleculin brain cancer therapy WP1122 gets FDA orphan drug status

Sep 06

Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Jul 11

Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial

Jul 08

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:MBRX - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	N/A	-29	N/A	N/A	2
12/31/2025	N/A	-28	N/A	N/A	2
12/31/2024	N/A	-27	N/A	N/A	2
9/30/2024	N/A	-30	-24	-24	N/A
6/30/2024	N/A	-25	-26	-26	N/A
3/31/2024	N/A	-27	-25	-25	N/A
12/31/2023	N/A	-30	-24	-24	N/A
9/30/2023	N/A	-26	-26	-26	N/A
6/30/2023	N/A	-29	-26	-26	N/A
3/31/2023	N/A	-30	-29	-29	N/A
12/31/2022	N/A	-29	-28	-28	N/A
9/30/2022	N/A	-25	-25	-25	N/A
6/30/2022	N/A	-21	-21	-21	N/A
3/31/2022	N/A	-18	-20	-20	N/A
12/31/2021	N/A	-16	-19	-19	N/A
9/30/2021	N/A	-16	-18	-18	N/A
6/30/2021	N/A	-15	-19	-19	N/A
3/31/2021	N/A	-21	-17	-17	N/A
12/31/2020	N/A	-17	-18	-18	N/A
9/30/2020	N/A	-19	-20	-19	N/A
6/30/2020	N/A	-19	-17	-17	N/A
3/31/2020	N/A	-10	-18	-18	N/A
12/31/2019	N/A	-13	-17	-17	N/A
9/30/2019	N/A	-12	-16	-16	N/A
6/30/2019	N/A	-10	-16	-15	N/A
3/31/2019	N/A	-14	-14	-13	N/A
12/31/2018	N/A	-12	-13	-12	N/A
9/30/2018	N/A	-12	-12	-11	N/A
6/30/2018	N/A	-13	N/A	-10	N/A
3/31/2018	N/A	-11	N/A	-9	N/A
12/31/2017	N/A	-10	N/A	-7	N/A
9/30/2017	N/A	-8	N/A	-6	N/A
6/30/2017	N/A	-7	N/A	-5	N/A
3/31/2017	N/A	-4	N/A	-5	N/A
12/31/2016	N/A	-4	N/A	-4	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: MBRX devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: MBRX devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: MBRX devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de MBRX devraient croître plus rapidement que le marché US.

Croissance élevée des revenus: MBRX ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de MBRX devrait être élevé dans 3 ans

Moleculin Biotech Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased to US$8.67

Price target decreased to US$11.67

Price target increased to US$21.50

Price target increased to US$23.50

Price target decreased to US$19.00

Forecast to breakeven in 2024

Recent updates

New major risk - Shareholder dilution

Moleculin Biotech, Inc. Announces New Findings Supporting the Ability of Annamycin Overcomes Resistance to Venetoclax in AML

Moleculin Biotech, Inc. Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

New minor risk - Profitability

New major risk - Financial position

Moleculin Biotech, Inc. to Report Q3, 2024 Results on Nov 08, 2024

New major risk - Share price stability

Moleculin Biotech, Inc., Annual General Meeting, Oct 24, 2024

New major risk - Shareholder dilution

Moleculin Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $5.497817 million.

Moleculin Biotech, Inc. Announces Plans for MIRACLE Phase 3 Pivotal Trial

Moleculin Biotech, Inc. has filed a Follow-on Equity Offering.

Moleculin Biotech, Inc. Completes End of Phase 2 Meeting with FDA for Annamycin in AML

Moleculin Biotech, Inc. Announces Additional Positive Preliminary Interim Data from AML Clinical Trial

New major risk - Market cap size

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (Nu 21C06)

Moleculin Biotech, Inc. to Report Q1, 2024 Results on May 10, 2024

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data

Moleculin Biotech, Inc. Announces Formation of Annamycin Scientific Advisory Board and Inaugural Appointment of Martin Tallman

New major risk - Market cap size

Moleculin Biotech, Inc Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial

New major risk - Financial position

New major risk - Share price stability

Moleculin Biotech, Inc. to Report Fiscal Year 2023 Results on Mar 22, 2024

Moleculin Biotech, Inc. Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Moleculin Biotech, Inc. Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3

Moleculin Biotech, Inc. announced that it expects to receive $9.01739 million in funding

We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

New major risk - Financial position

Moleculin Biotech, Inc. Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months

Moleculin Biotech, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Moleculin Biotech Receives an Extension of the 180 Calendar Days from Nasdaq to Regain Compliance with the Bid Price Requirement

New major risk - Share price stability

Moleculin Biotech, Inc. Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Moleculin Biotech, Inc. Announces New Positive Independent Report of No Cardiotoxicity in Annamycin

New major risk - Financial position

Moleculin Biotech, Inc. Provides Update on Ongoing Clinical Trials

Moleculin Biotech, Inc. to Report Q2, 2023 Results on Aug 11, 2023

Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?

Moleculin Biotech, Inc., Annual General Meeting, Jun 15, 2023

Moleculin Biotech Receives Non-Compliance Notice From Nasdaq

Moleculin Biotech, Inc. to Report Q1, 2023 Results on May 11, 2023

Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?

Moleculin Biotech, Inc. Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Moleculin Biotech, Inc. Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia

Moleculin Biotech, Inc. Receives FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme

Founder recently bought US$58k worth of stock

Founder recently bought US$108k worth of stock

Price target decreased to US$8.67

Moleculin Biotech, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Moleculin Biotech, Inc Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

Moleculin Biotech, Inc. Announces WP1096 Molecule Will Be Evaluated in Animal Studies Through the Preclinical Services Offered by the National Institute of Allergy and Infectious Diseases

Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies

Moleculin brain cancer therapy WP1122 gets FDA orphan drug status

Moleculin Biotech, Inc. Announces Completion of Third Single Ascending Dose Cohort in Phase 1A Clinical Trial of Wp1122 in the UK

Price target decreased to US$11.67

Price target increased to US$21.50

Moleculin Concludes Phase 1B and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Moleculin Biotech, Inc. Announces Completion of Second Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial

Moleculin Biotech, Inc. Announces Completion of First Single Ascending Dose (Sad) Cohort in Phase 1A Clinical Trial of Wp1122 in the UK

Moleculin Biotech, Inc. Announces the Commencement of Dosing in Its First-In-Human Phase 1A Study to Evaluate the Safety and Pharmacokinetics (PK) of Wp1122 in Healthy Volunteers for the Treatment of COVID-19 (MB-301)

Moleculin Biotech, Inc. Announces the Commencement of Dosing in Its First-In-Human Phase 1A Study to Evaluate the Safety and Pharmacokinetics (PK) of Wp1122 in Healthy Volunteers for the Treatment of COVID-19 (MB-301)

Moleculin Biotech, Inc Receives Approval from the UK's Medicines and Healthcare Products Regulatory Agency for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

Moleculin Biotech, Inc. Receives Allowance to Proceed with Phase 1/2 Study of Annamycin

Moleculin Biotech, Inc. Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer